To prevent the coronavirus disease 2019 (COVID-19) pandemic and aid restoration to prepandemic normality, global mass vaccination is urgently needed. Inducing herd immunity through mass vaccination has proven to be a highly effective strategy for preventing the spread of many infectious diseases, which protects the most vulnerable population groups that are unable to develop immunity, such as people with immunodeficiencies or weakened immune systems due to underlying medical or debilitating conditions. In achieving global outreach, the maintenance of the vaccine potency, transportation, and needle waste generation become major issues. Moreover, needle phobia and vaccine hesitancy act as hurdles to successful mass vaccination. The use of dissolvable microneedles for COVID-19 vaccination could act as a major paradigm shift in attaining the desired goal to vaccinate billions in the shortest time possible. In addressing these points, we discuss the potential of the use of dissolvable microneedles for COVID-19 vaccination based on the current literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144974 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics14051066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological and in Silico Insights into Male Infertility: Agerelated Trends and Anti-sperm Antibodies Post COVID-19 Vaccination.
Curr Med Chem
January 2025
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Background: Infertility was often considered a female issue, but male infertility emerged significantly after the Covid-19 pandemic. Hence, assessments are crucial for planning policies on health care and family planning and reasons thereof post vaccinations.
Material And Methods: The present study was a case-control, dual-centers, prospective study with normal sperm parameters.
SARS-CoV-2 surveillance in a hospital and control of an outbreak on a geriatric ward using whole genome sequencing.
Infect Prev Pract
September 2024
SARS-CoV-2 Sequencing Consortium, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Background: During the SARS-CoV-2 pandemic, dominant viral variants were repeatedly replaced by new variants with altered properties, frequently changing the dynamics of the infection event, as well as the effectiveness of vaccines and therapeutics. SARS-CoV-2 variant monitoring by whole genome sequencing was established at the University Medical Center Mainz, Germany to support patient management during the pandemic.
Methods: SARS-CoV-2 RNA samples from the University Medical Center were analysed weekly with whole genome sequencing.
Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024.
Vaccine X
October 2024
WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
We conducted a test negative study from November 2023 to June 2024, enrolling 4,367 children hospitalized with acute respiratory illness in Hong Kong. Among the children who tested negative for influenza virus and SARS-CoV-2, 56.8 % had received influenza vaccination.
View Article and Find Full Text PDFEvaluation of vaccine perceptions in Israel's Elderly: A Comparative study of COVID-19 and influenza vaccination attitudes.
Vaccine X
October 2024
Clinical Microbiology Laboratory, Tzafon Medical Center, Poriya, Israel, affiliated with Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Purpose: This study aimed to evaluate the attitudes of Israeli elderly population towards COVID-19 and influenza vaccines, and to assess factors contributing to these attitudes.
Methods: Four-hundred and one participants exhibiting symptoms consistent with COVID-19 or influenza were enrolled and filled out a questionnaire. A second questionnaire was filled out for hospitalized patients at discharge.
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.
BMJ Oncol
December 2023
Université Franche-Comté, INSERM, EFS BFC, UMR1098 RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Objective: Vaccinated patients with cancer in follow-up studies showed a high seropositivity rate but impaired antibody titres and T cell responses following mRNA vaccine against COVID-19. Besides clinical characteristics and the type of anticancer treatment before vaccination, the identification of patients susceptible to non-response following vaccination using immunological markers is worth to be investigated.
Methods And Analysis: All patients (n=138, solid cancers) were included in the CACOV-VAC Study comprising three cohorts ((neo)-adjuvant, metastatic and surveillance).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!